We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cerexa has reports positive results from the Phase II trial of Ceftaroline for the treatment of complicated skin and skin structure infections (cSSSI).
Northfield Laboratories has announced that patient enrollment is complete in its Phase III study of PolyHeme, a human hemoglobin-based, oxygen-carrying red blood cell substitute.
Aurobindo Pharma received tentative approval for a fixed-drug combination product containing Lamivudine150-mg and Zidovudine 300-mg tablets copackaged with Abacavir 300-mg tablets used in the treatment of HIV-1 infection.
Barr Laboratories has it received final approval from the FDA for its application to manufacture and market a generic version of Pfizer's Xanax XR (alprazolam extended-release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg.
Ono Pharmaceutical and Medarex have filed an investigational new drug application with the FDA for MDX-1106, a fully human anti-PD-1 antibody for the treatment of cancer.
Momenta Pharmaceuticals announced that it has submitted an electronic investigational new drug application to the FDA to begin a Phase I study of M118, the company's lead development candidate.
Genitope announced that its independent data safety monitoring board (DSMB) reviewed the second planned interim analysis of data for efficacy in its Phase III clinical trial for treatment of follicular non-Hodgkin's lymphoma (NHL) and recommended that the trial continue as planned.